MedTrace Logo

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

NCT01767636 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-03-03

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking blood flow to the tumor.

Conditions

  • Carcinoma of the Collecting Ducts of Bellini
  • Chromophobe Renal Cell Carcinoma
  • Kidney Medullary Carcinoma
  • Kidney Oncocytoma
  • Metastatic Renal Cell Cancer
  • Papillary Renal Cell Carcinoma
  • Recurrent Renal Cell Carcinoma
  • Sarcomatoid Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer

Interventions

DRUG

Pazopanib Hydrochloride

Given PO

Sponsors & Collaborators

Principal Investigators

  • Brian Costello, M.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-16
Primary Completion
2019-02-02
Completion
2021-01-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01767636 on ClinicalTrials.gov